Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 23, 2017
Which drugs does patent 6,315,720 protect, and when does it expire?
| Title: | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| Abstract: | Improved methods for delivering to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug are disclosed. The methods are of the type in which prescriptions for the drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber, pharmacy and patient have been properly registered in the medium before the patient is approved to receive the drug. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to the side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved. |
| Inventor(s): | Williams; Bruce A. (Flemington, NJ), Kaminski; Joseph K. (Hampton, NJ) |
| Assignee: | Celgene Corporation (Warren, NJ) |
| Application Number: | 09/694,217 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Formulation; Device; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-001 | Feb 8, 2013 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE | ||||
Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-002 | Feb 8, 2013 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE | ||||
Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE | ||||
Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | ► Subscribe | ► Subscribe | USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | RX | Yes | No | ► Subscribe | ► Subscribe | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | RX | Yes | Yes | ► Subscribe | ► Subscribe | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) | ||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,561,977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| 8,626,531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| 7,959,566 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| 6,869,399 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| 8,315,886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| 6,755,784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| 7,141,018 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 1437201 | ► Subscribe | |||||||||||||
| Australia | 2005201675 | ► Subscribe | |||||||||||||
| Australia | 780486 | ► Subscribe | |||||||||||||
| Brazil | 0016903 | ► Subscribe | |||||||||||||
| Canada | 2352629 | ► Subscribe | |||||||||||||
| China | 1425167 | ► Subscribe | |||||||||||||
| European Patent Office | 1330765 | ► Subscribe | |||||||||||||
| European Patent Office | 1970827 | ► Subscribe | |||||||||||||
| European Patent Office | 2226740 | ► Subscribe | |||||||||||||
| Israel | 150307 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,997 others who get our Drug Patent Expiration Alerts:
